Q-omics provides the consensus-scored SNHG29 profile across patient tissues and cancer cell-line models. SNHG29 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNHG29 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SNHG29 RNA expression shows 18,212 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where SNHG29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG29 survival associations across molecular data types. SNHG29 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG29 RNA expression–survival associations across cancer types. High SNHG29 expression shows unfavorable associations in ACC, LIHC, BLCA and KICH, but favorable associations in KIRC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNHG29 RNA expression.
This table summarizes SNHG29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG29 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, LIHC, CHOL and COAD. The KIRC box plot shows higher SNHG29 RNA expression in tumor versus normal tissue (log2 FC = +0.510, t-test p < 0.001).
This table shows molecular features associated with SNHG29 in patient tissues and cancer cell lines. In patient samples, SNHG29 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNHG29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
